and by the liver.
The clinical use of this hormone, which is potentially high, is still limited by its availability. Only a very small quantity of the hormone can be obtained from human kidneys. Its production as a recombinant protein can be performed but animal cells must be used for this purpose. The hormone is N and 0 glycosylated and bacteria cannot generate the molecule in its fully functional state (Jelkmann, 1992; Delorme et al, 1992) . Human EPO is produced by different animal cell lines (Takeuchi et al, 1989; Yanagi et al, 1989; Delorme et al, 1992; Nimtz et al, 1993; Lopez et al, 1994) and by yeast (Elliot et al, 1989) . The recombinant hormone produced by animal cells in culture is biologically active although not glycosylated as the native molecule (Davis et al, 1987 Houdebine, 1994 Houdebine, , 1995 . The regulatory regions from different milk protein genes are used for this purpose. Among these DNA sequences, the upstream region of the rabbit whey acidic protein (WAP) gene has been shown to direct the expression of foreign genes with high efficiency .
Mice are commonly used to evaluate the efficiency of gene constructs to be used in larger animals. Rabbits are considered as a possible species to produce recombinant proteins in sufficient quantity for pharmaceutical use (Houdebine, 1994) .
In the present work, the cDNA and the gene coding for the human EPO have been fused LO the rabbit WAP gene promoter.
Four constructs were used. They were tested in the mouse mammary cell line HC11. One and three of them were used to generate transgenic mice and rabbits, respectively.
MATERIALS AND METHODS

Gene constructs
The plasmid p1 contained the rabbit WAP gene promoter (6.3 Kb) used in our previous study and the complete human EPO gene with its own transcription terminator (Pugh et al, 1991; Lopez et al, 1994 ). The plasmid p2 was similar to the p1 but the EPO gene transcription terminator was replaced by the rabbit WAP gene fragment (3.9 Kb) containing the transcription terminator. The plasmid p3 contained the rabbit WAP gene promoter, a 5'UTR, which stimulates translation. This element was used in a previous study (Petitclerc et al, 1995) and will be described elsewhere: the EPO cDNA (Lopez et al, 1994) , the SV40 late gene intron, VP1, and the SV40 late gene terminator. These two latter elements are present in the vector pSVL (Amersham, Les Ulis, France). All these elements were bordered by two matrix attached regions (MAR).
In the 5'P end, the MAR located in the 3'OH human end of the apolipoprotein B100 gene (Levy-Wilson and Fortier, 1989) was added before the WAP gene promoter. In the 3'OH end, two copies of the SV40 MAR (Pommier et al, 1990) were added after the SV40 terminator. The plasmid p4 contained the rabbit WAP gene promoter followed by the entire human growth hormone (hGH) gene. The hEPO cDNA associated to the 5'UTR described earlier was introduced in the last exon of the hGH gene, at the Aspl site. This sequence allows a reinitiation of mRNA translation (unpublished data).
All these plasmids were in pPolylll (Lathe et ai, 1987) and are shown in figure 1. The inserts for microinjection were released from the plasmids after digestion with Not I.
Cell transfection
The mouse mammary cell line HC11 was transfected by lipofectin as recommended by the manufacturer. In all cases cells were transfected 1 day after trypsinization. Two plasmids were cotransfected: the plasmids containing the EPO gene (8 f l9) and the plasmid pRSVneo r for clone selection (2 f l9) for each 60 mm diameter dish.
Each transfection was carried out in two dishes.
The mixted clones were amplified, cultured in 10% fetal calf serum containing 10 ng/mL EGF and insulin (5 pg/mL) until hyperconfluency. Induction was performed by adding insulin (5 flg/mL), dexamethasone (10-6 M) and prolactin (5 gg/mL) in the medium without EGF as described by Ball et al (1988) . After 2 days, the media were collected and EPO concentration was estimated using a commercial kit (Lopez et al, 1994 ).
Generation of transgenic mice and rabbits Transgenic mice were obtained by injecting 1-2pl of linear inserts corresponding to about 500 copies of the genes. Transgenic rabbits were obtained in the same way, following the protocol described in our previous work (Massoud et al, 1991; Dunn et al, 1995) .
Transgenes were identified by PCR from ear DNA extracted by Gene-Clean as previously described (Semenza et al, 1991; Blanchard et al, 1992; Semenza and Wang, 1992; Maxwell et al, 1993 
DISCUSSION
The experiments depicted here show with no ambiguity that hEPO can be obtained in milk from transgenic animals. The possibility to use transgenic animals as an alternative to cultured cells to produce hEPO has been examined by several groups. Transgenic rabbits secreting very low levels of hEPO in their milk have been obtained (Castro et al, 1994) . A transgenic calf has also been generated (Hyttinen et al, 1994) . The efficiency of the transgene is still unknown.
In the present work, several gene constructs expressing hEPO gene were used. The construct p2 was only moderately efficient in mice and rabbit. This is in clear contrast with the HC11 cells which expressed this construct at a high level. Transgenes are known to be much better expressed when their transcribed region was native genes with their introns rather then cDNA (Palmiter et al, 1991; Petitclerc et al, 1995) . Unexpectedly, the hEPO gene, even devoid of its 3'OH flanking sequence, was poorly efficient. The introns may contain silencers which reduce the expression of the hEPO gene in non-renal and -liver cells.
The construct p3 was perhaps more potent but still quite insufficient to envisage a commercial utilization of the transgenic rabbits.
The stability of the hEPO in mouse and rabbit milk was not evaluated. Although unlikely, such an instability might explain why the hEPO did not accumulate in the milk transgenic animals.
With the construct p4, the health of the transgenic rabbits were obviously severely impaired. This is clearly due to an ectopic expression of the transgene. Previous work showed that the WAP promoter present in transgenes is active preferentially but not strictly in the mammary gland . The presence of hEPO in blood in males as in females resulted in exceeding red blood cell numbers, a fact already observed in transgenic mice harboring the native EPO gene (Semenza et al, 1989 (Semenza et al, , 1990 (Semenza et al, , 1991 . EPO produced by different tissues of the transgenic rabbits obviously altered several biological functions of the animals.
In some cases, the ectopic expression of transgenes can be strongly reduced by the presence of insulators added on both sides of the constructs. In these conditions as well, all the animals express the transgenic in a copy-dependent manner. The number of identified insulators is small and their mechanism of action is still poorly understood (Sippel et al, 1996) . Such an approach has been retained by Hyttinen et al (1994 (Attal et al, 1996) . Insulating transgenes will probably be possible in the future. The possibility to switch off and on a transgene by inducers or repressors such as tetracycline also offers an interesting perspective in this respect (Furth et al, 1994 and bGH (Th6pot et al, 1995) in their milk. Hence, it may be expected that even animals in which the hEPO transgene is conveniently insulated will suffer from excess of the hormone transferred from milk to blood as soon as their lactation starts. This will be particularly crucial in the rabbit in which milk synthesis starts 2 weeks before parturition .
A possible alternative consists of producing a biologically inactive precursor of hEPO followed by an in vitro biochemical activation; however, this is probably a diffi-icult task.
Another possibility might be to use an animal species in which the hEPO is only weakly active. It is not certain, however, that transgenesis can be performed easily in such a species.
The present work suggests that transgenic animals are probably not good candidates to produce recombinant hEPO in their milk. Interestingly, the direct transfer of the hEPO gene to somatic cells by adenoviral vectors offers attractive new possibilities (Tripathy et al, 1994) .
